This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab in combination with bevacizumab and chemotherapy as first-line treatment for advanced mesothelioma.
Both male and female patients aged 18 to 75 years (inclusive).
Histopathologically confirmed advanced mesothelioma.
No prior systemic therapy.
At least one measurable lesion according to mRECIST 1.1 and RECIST 1.1 criteria.
Prior systemic anti-tumor therapy, except for patients who relapsed more than six months after completion of adjuvant chemotherapy.
Known history of hypersensitivity to macromolecular protein preparations, or contraindication or allergy to any component of iparomlimab and tuvoraleimab, bevacizumab, pemetrexed, or platinum-based agents.
Major surgery (excluding diagnostic laparoscopy; local surgical treatment of isolated lesions is acceptable) within 28 days before the first dose.
History of allogeneic tissue/solid organ transplantation.